Semaglutide, tirzepatide and other GLP-1 drugs appear to provide significant value for patients with moderate PAD.

According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation. 

Ticagrelor, an antiplatelet medication from AstraZeneca commonly prescribed by cardiologists, gained FDA approval back in 2011. The author of a new investigative report, however, is raising several concerns about the data used to secure that approval.

The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.

The historic procedure was performed in Texas on a 45-year-old patient who had been hospitalized for months with advanced heart failure.

The STS Risk Calculator App, available on both iOS and Android devices, gives users improved access to real-time risk assessments.

Kenneth Margulies, MD, will be the group's next president. These new terms all begin after the HFSA Annual Scientific Meeting in September.

Widaplik, the new polypill from George Medicines, includes telmisartan, amlodipine and indapamide. The FDA's decision comes after positive data were published in both JACC and The Lancet.

New first-in-human data highlight the potential of pants designed to improve the quality of MRI-based cardiac stress tests.

Patients treated with the Sapien 3 platform from Edwards Lifesciences and the Evolut platform from Medtronic were linked to more similarities than differences after six years. This was a single-center study, researchers noted, but it does provide an in-depth look at the safety and effectiveness of TAVR.

Federal lawmakers have a fresh resource to keep them up on healthcare AI that falls outside of formal FDA oversight. It comes in the form of a new report from the nonprofit Bipartisan Policy Center.

Patients who frequently use AI tend to readily trust AI-assisted diagnoses made by their physicians. Counterintuitively, however, those who would rank themselves among the very best-informed about AI tend to mistrust such diagnoses.